➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Moodys
Johnson and Johnson
Dow
McKinsey

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,388,159

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,388,159 protect, and when does it expire?

Patent 9,388,159 protects ERLEADA and is included in one NDA.

This patent has sixty-nine patent family members in eighteen countries.

Summary for Patent: 9,388,159
Title:Substituted diazaspiroalkanes as androgen receptor modulators
Abstract: This invention provides for compounds of the Formula II: ##STR00001## wherein A, B, Het, R.sub.1, R.sub.2 and R.sub.3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
Inventor(s): Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:14/318,234
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,388,159
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,388,159

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,388,159

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007243651   Start Trial
Brazil PI0709771   Start Trial
China 101454002   Start Trial
Cyprus 1114623   Start Trial
Cyprus 1117540   Start Trial
Cyprus 1117958   Start Trial
Cyprus 1118026   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Baxter
Harvard Business School
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.